Sutro Biopharma has been granted a patent for hemiasterlin derivatives, conjugates, and compositions for treating cell proliferation and cancer. The compounds, including those in Formula 1000, offer methods for detection and diagnosis of cell proliferation and cancer. GlobalData’s report on Sutro Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Sutro Biopharma Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Sutro Biopharma, Nanoparticle drug conjugates was a key innovation area identified from patents. Sutro Biopharma's grant share as of February 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.

Hemiasterlin derivatives for treating cell proliferation and cancer

Source: United States Patent and Trademark Office (USPTO). Credit: Sutro Biopharma Inc

A recently granted patent (Publication Number: US11866515B2) discloses a compound represented by Formula 1000, along with various derivatives and salts. The compound is characterized by the presence of a divalent five- or six-membered monocyclic heteroaryl, a six-membered monocyclic aryl, or a fused bicyclic aryl or heteroaryl group. Additionally, the patent covers pharmaceutical compositions containing the compound along with suitable excipients, carriers, or diluents for therapeutic applications.

Furthermore, the patent encompasses specific variations of the compound, including different substituents and configurations, as well as the absence or presence of certain chemical groups like L. The pharmaceutical compositions described in the patent are intended for use in various therapeutic applications, leveraging the unique properties of the compound and its derivatives. Overall, the patent provides a comprehensive protection for the compound and its pharmaceutical formulations, paving the way for potential advancements in the field of drug development and treatment modalities.

To know more about GlobalData’s detailed insights on Sutro Biopharma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies